Heart Failure

Disclaimer: This document provides comprehensive medical information for educational and reference purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Clinicians must exercise their independent medical judgment in all patient care decisions, considering individual patient circumstances, local guidelines, and the most current evidence. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to patient care.

---

Overview

• Definition: Heart failure (HF) is a complex clinical syndrome resulting from structural or functional impairment of ventricular filling or ejection of blood. This leads to a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress, manifesting as characteristic symptoms (e.g., dyspnea, fatigue) and signs (e.g., peripheral edema, rales) due to inadequate tissue perfusion and/or pulmonary/systemic venous congestion. HF is a progressive disease.
• Epidemiology:
  • Affects over 6 million adults in the United States and over 26 million worldwide.
  • Prevalence is increasing due to an aging population and improved survival from other cardiovascular diseases (e.g., myocardial infarction).
  • Incidence increases sharply with age, affecting >10% of individuals over 70 years.
  • Leading cause of hospitalization in adults over 65 years.
  • Significant economic burden on healthcare systems due to hospitalizations, medications, and long-term care.
• Classification:
  • By Left Ventricular Ejection Fraction (LVEF):
    • Heart Failure with Reduced Ejection Fraction (HFrEF): LVEF ≤ 40%. Previously known as systolic heart failure.
    • Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF): LVEF 41-49%. Intermediate category, previously "mid-range."
    • Heart Failure with Preserved Ejection Fraction (HFpEF): LVEF ≥ 50%. Previously known as diastolic heart failure. Requires evidence of structural/functional cardiac abnormalities consistent with impaired diastolic filling or elevated filling pressures (e.g., elevated natriuretic peptides, diastolic dysfunction on echo).
  • By Clinical Course:
    • Acute Heart Failure (AHF): New onset or acute decompensation of chronic HF, often presenting with rapid onset of symptoms severe enough to require urgent medical attention or hospitalization.
    • Chronic Heart Failure: Stable, long-term condition requiring ongoing management.
  • By ACC/AHA Stages of Heart Failure (Progressive Nature):
    • Stage A: At high risk for HF but without structural heart disease or symptoms of HF (e.g., hypertension, diabetes, obesity, CAD).
    • Stage B: Structural heart disease present but without signs or symptoms of HF (e.g., LV hypertrophy, previous MI, asymptomatic valvular disease, LVEF ≤ 40%).
    • Stage C: Structural heart disease with prior or current signs and symptoms of HF.
    • Stage D: Refractory HF requiring specialized interventions.
  • By NYHA Functional Classification (Severity of Symptoms):
    • Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea.
    • Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, or dyspnea.
    • Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
    • Class IV: Unable to carry on any physical activity without discomfort. Symptoms of HF at rest. If any physical activity is undertaken, discomfort is increased.

Pathophysiology

• Mechanism: HF is characterized by a complex interplay of myocardial dysfunction (systolic, diastolic, or both), neurohormonal activation, inflammation, and remodeling.
  • Initial Insult: Myocardial injury (e.g., MI, viral myocarditis, chronic pressure/volume overload from HTN/valvular disease) leads to reduced cardiac output and/or increased filling pressures.
  • Compensatory Mechanisms (Maladaptive Over Time):
    • Frank-Starling Mechanism: Increased preload to optimize stroke volume, but limited in severe HF.
    • Neurohormonal Activation:
      • Renin-Angiotensin-Aldosterone System (RAAS): Activated by reduced renal perfusion and sympathetic stimulation, leading to vasoconstriction (angiotensin II), sodium/water retention (aldosterone), and myocardial remodeling (fibrosis, hypertrophy).
      • Sympathetic Nervous System (SNS): Increased catecholamine release (norepinephrine, epinephrine) to maintain cardiac output, leading to increased heart rate, contractility, and peripheral vasoconstriction. Chronic activation is detrimental, causing down-regulation of beta-receptors, arrhythmias, and apoptosis.
      • Vasopressin (ADH): Promotes water reabsorption, contributing to hyponatremia and fluid overload.
      • Natriuretic Peptides (BNP, ANP): Released in response to myocardial stretch (volume overload). Act as vasodilators and natriuretics, counteracting RAAS/SNS, but their beneficial effects are often overwhelmed in advanced HF.
    • Ventricular Remodeling: Progressive changes in ventricular size, shape, and function. Initially adaptive (e.g., concentric hypertrophy in pressure overload, eccentric hypertrophy in volume overload), but over time becomes maladaptive, leading to increased wall stress, fibrosis, apoptosis, and progressive decline in myocardial function.
• Risk Factors:
  • Coronary Artery Disease (CAD)/Myocardial Infarction (MI) – most common cause of HFrEF
  • Hypertension (HTN) – most common cause of HFpEF
  • Diabetes Mellitus (DM)
  • Obesity
  • Valvular Heart Disease (e.g., aortic stenosis, mitral regurgitation)
  • Cardiomyopathies (dilated, hypertrophic, restrictive, arrhythmogenic)
  • Chronic Kidney Disease (CKD)
  • Atrial Fibrillation (AF)
  • Thyroid Disorders (hypo- or hyperthyroidism)
  • Excessive Alcohol Consumption
  • Smoking
  • Certain Medications (e.g., cardiotoxic chemotherapy, NSAIDs, some antiarrhythmics)
  • Illicit Drug Use (e.g., cocaine)
  • Sleep Apnea
  • Genetic Predisposition
• Protective Factors:
  • Aggressive management of hypertension and diabetes.
  • Lifestyle modifications: regular physical activity, healthy diet (e.g., DASH diet), smoking cessation, moderate alcohol intake.
  • Weight management and obesity prevention.
  • Early identification and treatment of CAD, valvular heart disease, and arrhythmias.
  • Vaccinations (e.g., influenza, pneumococcal) to prevent infections that can precipitate decompensation.

Clinical Presentation

Signs and Symptoms

Symptoms are often non-specific and may develop insidiously. Exertional symptoms are common initially, progressing to symptoms at rest as HF worsens.

• Cardinal Features (Common in both HFrEF and HFpEF):
  • Dyspnea: Shortness of breath, initially on exertion (DOE), progressing to dyspnea at rest.
  • Orthopnea: Dyspnea when lying flat, relieved by sitting up. Quantified by number of pillows.
  • Paroxysmal Nocturnal Dyspnea (PND): Sudden awakening at night with severe dyspnea, relieved by sitting upright or standing.
  • Fatigue/Weakness: Generalized tiredness, reduced exercise tolerance, feeling of being "run down."
  • Peripheral Edema: Swelling, typically in the ankles and lower legs, often bilateral and pitting. May extend to sacrum, abdomen (ascites).
• Early Signs (Often subtle or exertional):
  • Mild exertional dyspnea.
  • Unexplained fatigue.
  • Mild ankle swelling, especially at the end of the day.
  • Weight gain (due to fluid retention).
  • Nocturnal cough.
• Advanced Signs (Reflecting significant congestion or low cardiac output):
  • Dyspnea at rest.
  • Anasarca (generalized massive edema).
  • Ascites (abdominal swelling due to fluid).
  • Pulmonary rales/crackles extending up the lung fields.
  • Hypotension (in cardiogenic shock).
  • Signs of end-organ hypoperfusion (e.g., cool extremities, altered mental status).
  • Cardiac cachexia (severe muscle wasting).
• Atypical Presentations:
  • Elderly patients may present with non-specific symptoms like confusion, delirium, falls, nausea, decreased appetite, or generalized weakness without prominent dyspnea.
  • Patients with COPD or asthma may attribute dyspnea to their lung disease.
  • Right heart failure predominance can cause isolated peripheral edema, ascites, and abdominal discomfort without significant dyspnea.

Physical Examination

• General Appearance: Varies from comfortable at rest to acutely distressed, tachypneic, and diaphoretic. Cachexia may be present in advanced stages.
• Vital Signs: Tachycardia (due to SNS activation), tachypnea, hypotension or hypertension (depending on underlying cause and stage), pulsus alternans (alternating strong and weak pulse in severe LV dysfunction).
• Inspection:
  • Neck: Jugular Venous Distension (JVD) >4 cm above the sternal angle at 45 degrees, reflecting elevated right atrial pressure. Visible "a" or "v" waves.
  • Lungs: Increased respiratory effort, use of accessory muscles, cyanosis.
  • Extremities: Peripheral edema (pitting, bilateral), coolness (poor perfusion), pallor.
  • Abdomen: Abdominal distension (ascites), hepatojugular reflux (sustained increase in JVP >3 cm with firm pressure on the right upper quadrant for 10-15 seconds).
• Palpation:
  • Precordium: Displaced apical impulse (laterally and/or inferiorly) in LV enlargement. Sustained apical impulse (LV hypertrophy).
  • Abdomen: Hepatomegaly (tender, firm).
• Auscultation:
  • Cardiac:
    • S3 Gallop: Low-pitched extra heart sound in early diastole, best heard at the apex in left lateral decubitus position, indicative of rapid ventricular filling into a stiff or dilated ventricle (highly specific for HF).
    • S4 Gallop: High-pitched extra heart sound in late diastole, preceding S1, associated with forceful atrial contraction into a stiff ventricle (common in LV hypertrophy, less specific for HF).
    • Murmurs: Mitral regurgitation (common secondary to LV dilation), tricuspid regurgitation (secondary to pulmonary hypertension and RV dilation), aortic stenosis (potential cause of HF).
  • Pulmonary:
    • Crackles (Rales): Inspiratory, non-clearing sounds, typically starting at the bases, indicating pulmonary edema.
    • Wheezes: May be present ("cardiac asthma") due to bronchoconstriction from pulmonary congestion.
    • Diminished breath sounds: With pleural effusions.
• Special Tests:
  • Hepatojugular Reflux: As described under Inspection. Highly specific for elevated right heart pressures.

Diagnostic Approach

The diagnosis of HF is primarily clinical, supported by objective evidence of cardiac dysfunction.

History Taking

• Key Questions:
  • Symptom Onset and Progression: When did symptoms begin? How have they changed over time? Are they exertional or at rest?
  • Dyspnea: Presence of DOE, orthopnea, PND, number of pillows used, any sudden worsening?
  • Fluid Retention: Edema (location, pitting/non-pitting, daily variation), weight gain, abdominal swelling, changes in urination (nocturia).
  • Low Output Symptoms: Fatigue, weakness, reduced exercise tolerance, dizziness, lightheadedness.
  • Past Medical History: History of MI, HTN, DM, valvular disease, thyroid disease, AF, renal disease, congenital heart disease, sleep apnea.
  • Medication History: Current and past medications (especially cardiotoxic drugs, NSAIDs, calcium channel blockers [non-dihydropyridine in HFrEF]), adherence.
  • Social History: Smoking, alcohol, illicit drug use, diet, exercise habits.
  • Family History: Early heart disease, sudden cardiac death, cardiomyopathy.
  • Functional Status: NYHA functional class, ability to perform daily activities.
  • Recent Hospitalizations: For HF or other cardiac events.
• Red Flags:
  • Rapidly worsening dyspnea or edema.
  • Chest pain (suggesting acute coronary syndrome or worsening ischemia).
  • Syncope or pre-syncope (suggesting severe low cardiac output or arrhythmia).
  • Hemoptysis (pulmonary infarction, severe pulmonary hypertension).
  • Hypotension with signs of hypoperfusion (cardiogenic shock).

Laboratory Tests

• First-Line:
  • Natriuretic Peptides:
    • B-type Natriuretic Peptide (BNP): Normal < 100 pg/mL. Levels generally correlate with severity of HF.
    • N-terminal pro-B-type Natriuretic Peptide (NT-proBNP): Normal < 300 pg/mL (age-adjusted cutoffs vary, e.g., < 75 years < 125 pg/mL; 75-99 years < 450 pg/mL; > 99 years < 900 pg/mL).
    • Utility: Excellent negative predictive value to rule out HF in patients with dyspnea. Elevated in HF, but also in renal dysfunction, AF, pulmonary embolism, sepsis, elderly. Lower in obesity.
  • Complete Blood Count (CBC): Assess for anemia (can exacerbate HF) or infection.
  • Serum Electrolytes (Na, K, Cl): Baseline, monitor for diuretic side effects (hypokalemia, hyponatremia) and renal function changes.
  • Renal Function (BUN, Creatinine): Assess baseline kidney function and monitor for cardiorenal syndrome or diuretic-induced kidney injury.
  • Liver Function Tests (LFTs): May be elevated in right HF due to hepatic congestion.
  • Thyroid Stimulating Hormone (TSH): Rule out thyroid dysfunction as a cause or exacerbator of HF.
  • Fasting Glucose & HbA1c: Screen for or monitor diabetes.
  • Lipid Panel: Assess cardiovascular risk factors.
• Confirmatory (If indicated by clinical suspicion):
  • Cardiac Troponins (I or T): Elevated in acute MI or myocardial injury; can be mildly elevated in acute decompensated HF due to myocardial stretch or demand ischemia.
  • Iron Studies (Ferritin, Transferrin Saturation): Assess for iron deficiency (common in HF, even without anemia, and treatable).
  • Urinalysis: Screen for proteinuria, which indicates kidney disease.
• Monitoring:
  • Serum Electrolytes & Renal Function: Frequently (e.g., within 1-2 weeks of starting/titrating diuretics, ACEi/ARB/ARNI, MRA, SGLT2i), then periodically (e.g., every 3-6 months or as clinically indicated).
  • BNP/NT-proBNP: May be used to monitor disease progression or response to therapy, but primarily for diagnostic/prognostic purposes, not routine titration.
  • Weight: Daily monitoring for fluid retention.

Imaging

• Recommended:
  • Echocardiography (Transthoracic Echocardiogram - TTE): Cornerstone diagnostic test.
    • Purpose: Assesses LVEF, ventricular size and function (systolic and diastolic), wall motion abnormalities, valvular structure and function, estimated pulmonary artery pressures, presence of pericardial effusion. Essential for classifying HF as HFrEF, HFmrEF, or HFpEF.
    • Recommendation: All patients with suspected HF should have a TTE.
  • Chest X-ray (CXR):
    • Purpose: Assesses cardiomegaly (cardiothoracic ratio >0.5), pulmonary congestion (cephalization of pulmonary vessels, Kerley B lines, alveolar edema, pleural effusions), and identifies alternative causes of dyspnea (e.g., pneumonia, COPD exacerbation).
  • Electrocardiogram (ECG):
    • Purpose: Evaluate for prior MI (Q waves), LV hypertrophy (voltage criteria), arrhythmias (AF, VT), conduction abnormalities (bundle branch blocks, AV block), and ischemia. A normal ECG makes severe LV systolic dysfunction unlikely.
• Advanced (When needed for specific indications):
  • Cardiac Magnetic Resonance Imaging (CMR):
    • Purpose: Gold standard for precise assessment of ventricular volumes, LVEF, myocardial tissue characterization (e.g., fibrosis, inflammation, amyloidosis, sarcoidosis, iron overload). Useful when echo is inconclusive or for specific cardiomyopathies.
  • Cardiac Computed Tomography (CT):
    • Purpose: Primarily for evaluation of coronary artery disease (CT angiography), assessment of valvular heart disease (e.g., for TAVR planning), or to rule out pulmonary embolism in acute decompensation.
  • Nuclear Imaging (e.g., Myocardial Perfusion Imaging):
    • Purpose: Assess for inducible ischemia in patients with CAD or suspected CAD contributing to HF.
  • Invasive Hemodynamic Monitoring (Pulmonary Artery Catheterization):
    • Purpose: Used in select cases of acute decompensated HF (e.g., refractory congestion, hypotension, cardiorenal syndrome) to guide management by directly measuring intracardiac pressures and cardiac output.
  • Coronary Angiography:
    • Purpose: Indicated for patients with HF where CAD is suspected as the underlying cause or contributing factor, particularly if revascularization is a consideration.

Management

Management of HF is complex, multifaceted, and aims to improve symptoms, quality of life, prevent hospitalizations, and prolong survival.

Acute Management (Acute Decompensated Heart Failure - ADHF)

Focus on rapid symptom relief, hemodynamic stabilization, and identifying/treating precipitating factors.

• Immediate (First-hour interventions):
  • Assess Airway, Breathing, Circulation (ABCs).
  • Oxygen Supplementation: If SpO2 < 90% or signs of hypoxemia.
  • Positioning: Sit upright to reduce preload.
  • Intravenous (IV) Loop Diuretics: First-line for fluid overload. Furosemide 20-80 mg IV bolus (or oral dose equivalent), double prior oral dose for chronic HF patients. May start with continuous infusion (e.g., 5-10 mg/hour after bolus) if severe. Titrate based on urine output and clinical response.
  • Vasodilators:
    • IV Nitroglycerin: If blood pressure allows (SBP > 100-110 mmHg), especially with pulmonary edema. Start at 5-10 mcg/min IV, titrate up to 200 mcg/min. Reduces preload and afterload.
    • IV Sodium Nitroprusside: For severe hypertension with pulmonary edema; more potent, requires arterial line monitoring.
• Stabilization (Early management priorities):
  • Non-Invasive Positive Pressure Ventilation (NIPPV): BiPAP or CPAP for patients with acute respiratory failure due to cardiogenic pulmonary edema. Improves oxygenation, reduces work of breathing, and decreases preload/afterload.
  • Identification and Treatment of Precipitating Factors:
    • Myocardial Ischemia/Infarction (e.g., ACS protocol).
    • Arrhythmias (e.g., AF with rapid ventricular response - rate control/rhythm control).
    • Infections (e.g., pneumonia, sepsis).
    • Non-adherence to medications or diet.
    • Hypertensive crisis.
    • Acute valvular dysfunction.
    • Thyroid storm.
  • Inotropes (e.g., Dobutamine, Milrinone): Reserved for patients with hypoperfusion and low cardiac output despite optimal fluid status, or cardiogenic shock. Use with extreme caution due to proarrhythmic effects and increased mortality risk with long-term use.
• Emergency (Crisis management):
  • Cardiogenic Shock: Mechanical circulatory support (IABP, Impella, ECMO) may be considered in refractory cases.
  • Refractory Edema: Consider ultrafiltration or dialysis if diuretics are ineffective and renal function is worsening.

Chronic Management

Focus on Guideline-Directed Medical Therapy (GDMT), lifestyle modifications, and patient education.

• Pharmacological (GDMT is the cornerstone for HFrEF):
  • For HFrEF (LVEF ≤ 40%) - "Quadruple Therapy": Initiate and titrate to target doses or maximum tolerated doses.
    1. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) or ACE Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB):
       • ARNI (Sacubitril/Valsartan - Entresto): Recommended as first-line therapy for symptomatic HFrEF (NYHA class II-III) as a replacement for ACEi/ARB. Dosing: Start 24/26 mg BID, target 97/103 mg BID. Do not co-administer with ACEi (require 36-hour washout) or in patients with angioedema history.
       • ACE Inhibitor (e.g., Lisinopril, Enalapril, Ramipril): If ARNI not tolerated or contraindicated. Dosing: Lisinopril start 2.5-5 mg QD, target 20-40 mg QD. Enalapril start 2.5 mg BID, target 10-20 mg BID.
       • ARB (e.g., Valsartan, Candesartan, Losartan): If ACEi not tolerated due to cough. Dosing: Valsartan start 20-40 mg BID, target 160 mg BID.
    2. Beta-Blockers (BB): (Carvedilol, Metoprolol Succinate ER, Bisoprolol). Start low and titrate slowly (e.g., every 2 weeks) to target doses.
       • Carvedilol: Start 3.125 mg BID, target 25-50 mg BID.
       • Metoprolol Succinate ER: Start 12.5-25 mg QD, target 200 mg QD.
       • Bisoprolol: Start 1.25 mg QD, target 10 mg QD.
       • Contraindications: Symptomatic bradycardia, high-degree AV block without pacemaker, cardiogenic shock, acute decompensated HF (unless stable on diuretics and vasodilators).
    3. Mineralocorticoid Receptor Antagonists (MRAs): (Spironolactone, Eplerenone). For NYHA class II-IV HFrEF with LVEF ≤ 35% and CrCl > 30 mL/min, K < 5.0 mEq/L.
       • Spironolactone: Start 12.5-25 mg QD, target 25-50 mg QD.
       • Eplerenone: Start 25 mg QD, target 50 mg QD.
       • Monitor K and renal function closely.
    4. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: (Dapagliflozin, Empagliflozin). Recommended for all HFrEF patients, regardless of diabetes status, in addition to other GDMT.
       • Dapagliflozin (Farxiga): 10 mg QD.
       • Empagliflozin (Jardiance): 10 mg QD.
       • Side effects: Genitourinary infections, hypotension, euglycemic DKA (rare).
  • Other Pharmacological Therapies for HFrEF:
    • Diuretics (Loop Diuretics - e.g., Furosemide, Torsemide, Bumetanide): Manage fluid retention and symptoms. Not mortality benefit. Titrate to euvolemia. Furosemide 20-80 mg QD or BID.
    • Hydralazine and Isosorbide Dinitrate (BiDil): For self-identified Black patients with NYHA class III-IV HFrEF already on optimal GDMT (ACEi/ARB, BB, MRA), due to additional mortality benefit. Also for patients unable to tolerate ACEi/ARB. Start Hydralazine 25-50 mg TID/QID, ISDN 20-40 mg TID/QID.
    • Ivabradine (Corlanor): For symptomatic (NYHA class II-III) HFrEF with LVEF ≤ 35%, in sinus rhythm with resting HR ≥ 70 bpm despite maximum tolerated BB dose (or BB contraindication). Start 2.5-5 mg BID, target 7.5 mg BID.
    • Digoxin: For symptomatic HFrEF with reduced LVEF to reduce HF hospitalizations, especially for AF with rapid ventricular response. No mortality benefit. Maintain serum levels 0.5-0.9 ng/mL.
    • Vericiguat (Verquvo): Soluble guanylate cyclase stimulator for HFrEF (LVEF < 45%) in patients recently hospitalized or requiring IV diuretics for worsening HF. Start 2.5 mg QD, target 10 mg QD.
  • For HFpEF (LVEF ≥ 50%): Management focuses on symptom control and managing comorbidities.
    • SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): Now recommended to reduce HF hospitalizations and cardiovascular mortality. Empagliflozin 10 mg QD. Dapagliflozin 10 mg QD.
    • Diuretics: For symptom relief from congestion.
    • Aggressive Management of Comorbidities: Hypertension, AF, diabetes, CAD, obesity, sleep apnea, iron deficiency.
• Non-pharmacological:
  • Dietary Sodium Restriction: < 2-3 grams/day (or 1500 mg/day in severe HF). Strict adherence essential for symptom control.
  • Fluid Restriction: Generally not needed unless severe hyponatremia (Na < 130 mEq/L) or refractory congestion.
  • Regular Physical Activity: Supervised exercise rehabilitation for stable HF patients (NYHA class I-III) to improve exercise capacity and quality of life.
  • Weight Management: Maintain healthy body weight (BMI 20-25 kg/m²).
  • Smoking Cessation: Crucial.
  • Alcohol Moderation/Abstinence: Especially in alcoholic cardiomyopathy.
  • Vaccinations: Annual influenza vaccine and pneumococcal vaccine (PPSV23 and PCV13, as per guidelines).
  • Daily Weight Monitoring: Report weight gain > 2-3 lbs in 24 hours or 5 lbs in a week.
  • Patient Education: Disease process, medication adherence, symptom recognition, self-management.
• Monitoring:
  • Clinical Status: Symptoms (dyspnea, fatigue, edema), functional capacity (NYHA class), physical exam (JVD, edema, rales).
  • Weight: Daily.
  • Blood Pressure and Heart Rate: At each visit.
  • Laboratory Tests: Electrolytes, renal function, BNP/NT-proBNP (periodically), CBC, LFTs, glucose, HbA1c (as indicated).
  • Device Checks: For patients with ICDs/CRTs.
  • Quality of Life Assessment: Using validated questionnaires.
  • Referrals: Cardiac rehab, palliative care, advanced HF clinic.

Treatment Algorithms

The general approach for HFrEF involves sequential initiation and up-titration of GDMT.

• First-Line (For HFrEF):
  1. Diagnosis of HFrEF (LVEF ≤ 40%)
  2. Initiate Diuretics for congestion.
  3. Start ARNI (or ACEi/ARB if ARNI not suitable).
  4. Start Beta-Blocker.
  5. Start MRA.
  6. Start SGLT2 Inhibitor.
     • These four classes should be started and titrated to target doses in all eligible symptomatic HFrEF patients, ideally rapidly (e.g., within 4 weeks of diagnosis) and in parallel if possible, rather than strict sequential order for each drug class.
• Second-Line (For HFrEF, after optimal GDMT is achieved):
  • Consider Hydralazine/Isosorbide Dinitrate for self-identified Black patients, or those unable to tolerate ACEi/ARB.
  • Consider Ivabradine if HR ≥ 70 bpm in sinus rhythm despite BB.
  • Consider Digoxin for symptom control, especially with AF.
  • Consider Vericiguat for recent worsening HF.
• Refractory Cases (Advanced HF):
  • Cardiac Resynchronization Therapy (CRT-D): For HFrEF (LVEF ≤ 35%), NYHA class II-IV, in sinus rhythm with LBBB (QRS ≥ 150 ms strongly recommended, QRS 120-149 ms may be considered). Improves symptoms, QoL, and survival.
  • Implantable Cardioverter-Defibrillator (ICD): For primary prevention of sudden cardiac death in HFrEF (LVEF ≤ 35%) with NYHA class II-III symptoms despite ≥ 3 months of GDMT, and expected survival > 1 year. Also for secondary prevention in patients who survived VT/VF.
  • Left Ventricular Assist Device (LVAD): Mechanical circulatory support for patients with advanced HFrEF refractory to medical therapy, as bridge to transplant, destination therapy, or bridge to recovery.
  • Heart Transplantation: Definitive therapy for carefully selected patients with end-stage HF refractory to all other treatments.
  • Palliative Care/Hospice: For patients with advanced HF where goals shift from life prolongation to symptom management and quality of life.

Complications

• Common:
  • Acute Decompensated Heart Failure (ADHF): Frequent hospitalizations due to fluid overload or low cardiac output.
  • Arrhythmias: Atrial fibrillation (common, can worsen HF), ventricular tachycardia/fibrillation (risk of sudden cardiac death).
  • Renal Dysfunction (Cardiorenal Syndrome): Worsening kidney function secondary to reduced cardiac output or aggressive diuresis.
  • Hyponatremia: Common, often dilutional, associated with worse prognosis.
  • Iron Deficiency: Even without anemia, contributes to fatigue and poor exercise tolerance.
• Serious:
  • Sudden Cardiac Death (SCD): Often due to ventricular arrhythmias.
  • Cardiogenic Shock: Severe low cardiac output leading to end-organ hypoperfusion.
  • Pulmonary Hypertension: Can lead to right ventricular failure.
  • Thromboembolism: Increased risk of stroke (especially with AF) and systemic embolism.
• Long-term:
  • Cardiac Cachexia: Involuntary weight loss, muscle wasting, increased mortality.
  • Depression and Anxiety: Common psychological comorbidities, impacting QoL and self-care.
  • Sleep Apnea: Both obstructive and central sleep apnea are common and worsen HF prognosis.
  • Recurrent Hospitalizations: Significant impact on patient QoL and healthcare costs.

Prognosis

HF carries a significant morbidity and mortality burden.

• Factors Affecting Outcome:
  • LVEF: Lower LVEF generally indicates worse prognosis in HFrEF.
  • NYHA Functional Class: Higher class indicates more severe symptoms and worse prognosis.
  • Natriuretic Peptide Levels (BNP/NT-proBNP): Higher levels correlate with worse prognosis.
  • Renal Function: Worsening renal function is a strong predictor of adverse outcomes.
  • Comorbidities: Presence and severity of comorbidities (e.g., diabetes, CAD, COPD, anemia, depression).
  • Hospitalizations for HF: Prior hospitalizations for HF are associated with significantly increased risk of rehospitalization and mortality.
  • Age: Older age is generally associated with worse outcomes, but chronological age alone is not the sole determinant.
  • GDMT Adherence: Optimal GDMT significantly improves prognosis.
• Survival:
  • HF is a progressive disease with high mortality.
  • Overall 5-year survival rates vary widely depending on HF type, severity, and GDMT adherence, ranging from 30-50%.
  • Patients with NYHA Class IV HF have particularly poor prognosis, with 1-year mortality rates approaching 50%.
  • HFrEF generally has higher mortality rates than HFpEF, but the burden of morbidity and hospitalizations is high in both.
• Quality of Life:
  • Significantly impaired due to chronic symptoms, functional limitations, and frequent hospitalizations.
  • High rates of depression and anxiety further reduce QoL.
  • Goals of care increasingly include improvement in QoL and symptom burden.

Prevention

• Primary Prevention (Preventing initial occurrence of HF - ACC/AHA Stage A):
  • Risk Factor Modification:
    • Aggressive management of hypertension (target BP < 130/80 mmHg).
    • Optimal glycemic control in diabetes (HbA1c < 7%).
    • Lipid management (statins for dyslipidemia).
    • Weight management and prevention of obesity.
    • Smoking cessation.
    • Regular physical activity and a heart-healthy diet.
  • Avoidance of Cardiotoxins: Limit excessive alcohol intake, cautious use of cardiotoxic drugs (e.g., certain chemotherapies).
• Secondary Prevention (Preventing progression from structural heart disease to symptomatic HF - ACC/AHA Stage B):
  • For patients with asymptomatic LV systolic dysfunction (LVEF ≤ 40% without symptoms of HF), or prior MI/cardiac remodeling:
    • ACE Inhibitors/ARBs: Recommended to prevent symptomatic HF and reduce mortality.
    • Beta-Blockers: Recommended post-MI or in asymptomatic LV dysfunction to prevent symptomatic HF and reduce mortality.
    • SGLT2 inhibitors: Emerging evidence suggests benefit in preventing HF in high-risk patients (e.g., diabetes, CKD).
  • Management of Valvular Heart Disease: Timely intervention for severe asymptomatic valvular disease when indicated.
• Tertiary Prevention (Preventing complications and improving outcomes in established HF - ACC/AHA Stage C/D):
  • Optimal Guideline-Directed Medical Therapy (GDMT): Maximize use and titration of ARNI/ACEi/ARB, beta-blockers, MRAs, SGLT2 inhibitors.
  • Device Therapies: ICD for primary/secondary prevention of SCD, CRT for symptomatic HFrEF with wide QRS.
  • Cardiac Rehabilitation: Improves functional capacity and QoL.
  • Comprehensive HF Disease Management Programs: Multidisciplinary approach involving patient education, close monitoring, early intervention for decompensation.
  • Sodium and Fluid Restriction: As per dietary recommendations.

Special Populations

• Pediatric:
  • Etiology: Congenital heart disease (most common cause), viral myocarditis, hypertrophic cardiomyopathy, dilated cardiomyopathy.
  • Presentation: Often non-specific (e.g., poor feeding, failure to thrive, diaphoresis with feeding, rapid breathing). Older children may have exercise intolerance.
  • Management: Focus on managing underlying cause. Medications (digoxin, diuretics, ACEi, beta-blockers) are used but with specific pediatric dosing and monitoring.
• Geriatric:
  • Prevalence: HF incidence increases sharply with age. HFpEF is more common in the elderly.
  • Atypical Presentation: Symptoms may be vague (e.g., fatigue, confusion, falls), and classic HF signs may be blunted.
  • Comorbidities: Higher burden of comorbidities (CKD, anemia, AF, COPD) and polypharmacy, increasing risk of drug interactions and side effects.
  • Management: GDMT should be applied, but titration may be slower, and lower doses may be needed due to age-related changes in drug metabolism and renal function. Careful monitoring for hypotension and electrolyte imbalances. Focus on QoL.
• Pregnancy:
  • Etiology: Pre-existing HF (e.g., congenital heart disease, cardiomyopathy), peripartum cardiomyopathy (PPCM). PPCM usually presents in late pregnancy or within 5 months postpartum.
  • Management: Close monitoring and collaboration between cardiology and obstetrics.
    • ACE inhibitors, ARBs, ARNIs, MRAs: Contraindicated in pregnancy due to fetal harm.
    • Safe medications: Hydralazine, beta-blockers (avoid atenolol), diuretics (use with caution), digoxin.
    • Delivery: Carefully planned, often vaginal with epidural anesthesia to minimize hemodynamic stress.
• Comorbidities:
  • Chronic Kidney Disease (CKD): Common comorbidity, exacerbates HF and complicates management. Adjust GDMT doses, monitor electrolytes and renal function closely. SGLT2 inhibitors are beneficial.
  • Diabetes Mellitus (DM): SGLT2 inhibitors are particularly beneficial for HF patients with DM.
  • Atrial Fibrillation (AF): Common arrhythmia in HF, worsening symptoms and increasing stroke risk. Rate control (beta-blockers, digoxin) and rhythm control (cardioversion, ablation) strategies. Anticoagulation (DOACs preferred).
  • Anemia: Common, contributes to symptoms. Iron deficiency should be treated with IV iron, even if not anemic.
  • Obstructive Sleep Apnea (OSA): Highly prevalent. CPAP therapy can improve cardiac function and QoL.

Clinical Pearls

• HF is a Syndrome, Not a Diagnosis: Always seek to identify and manage the underlying cause(s) and precipitating factors.
• Natriuretic Peptides for Rule-Out: BNP/NT-proBNP are most useful for ruling out HF in patients with dyspnea when clinical suspicion is low.
• Echocardiogram is Essential: It's crucial for diagnosis, classification (HFrEF, HFmrEF, HFpEF), and guiding therapy.
• GDMT is Foundational for HFrEF: Aggressively initiate and titrate all four pillars of therapy (ARNI/ACEi/ARB, BB, MRA, SGLT2i) to target doses for improved outcomes.
• Patient Education is Key: Empower patients to manage their condition, recognize worsening symptoms, adhere to diet and medication, and monitor daily weights.
• Weight Monitoring: Daily weights are the most sensitive indicator of fluid retention in chronic HF. A sudden gain of 2-3 lbs in 24 hours or 5 lbs in a week warrants medical attention.
• Holistic Approach: Beyond medications, address lifestyle, comorbidities, psychosocial factors, and consider palliative care early for advanced stages.

Recent Updates

• Guidelines: The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure and the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure are the most current comprehensive recommendations.
• Evidence:
  • SGLT2 Inhibitors: Now established as a foundational therapy for all HFrEF patients, regardless of diabetes status, based on trials like DAPA-HF (dapagliflozin) and EMPEROR-Reduced (empagliflozin).
  • SGLT2 Inhibitors for HFpEF: EMPEROR-Preserved (empagliflozin) and DELIVER (dapagliflozin) trials have demonstrated that SGLT2 inhibitors significantly reduce HF hospitalizations and cardiovascular death in HFpEF and HFmrEF, making them the first drug class with a strong positive outcome for this challenging population.
  • Vericiguat: VICTORIA trial showed it reduced the composite endpoint of CV death or HF hospitalization in HFrEF patients with recent worsening HF.
  • Iron Deficiency Treatment: IV iron therapy (e.g., ferric carboxymaltose) has been shown to improve symptoms, exercise capacity, and QoL in symptomatic HFrEF patients with iron deficiency (even without anemia) based on trials like FAIR-HF, CONFIRM-HF, AFFIRM-AHF.
• Controversies:
  • Optimal timing and sequencing of HFrEF GDMT: While all four pillars are recommended, the best strategy for rapid initiation and titration (simultaneous vs. sequential) is an area of ongoing discussion and clinical practice variation.
  • Role of natriuretic peptides in guiding therapy: While useful for diagnosis and prognosis, routine use to guide dose titration is not universally recommended.
  • Management of HFmrEF: This intermediate group (LVEF 41-49%) now has clearer guidance with the recommendation for SGLT2 inhibitors and consideration of HFrEF GDMT.

Key References

• Guidelines:
  • Heidenreich, P. A., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18), e895-e1032.
  • McDonagh, T. A., et al. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 42(36), 3599-3726.
• Landmark Studies:
  • ARNI: Packer, M., et al. (2015). Angiotensin Receptor–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine, 372(24), 2439-2448. (PARADIGM-HF trial)
  • SGLT2i (HFrEF): McMurray, J. J. V., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381(20), 1995-2008. (DAPA-HF trial); Packer, M., et al. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 383(15), 1413-1424. (EMPEROR-Reduced trial)
  • SGLT2i (HFpEF/HFmrEF): Anker, S. D., et al. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 385(16), 1451-1460. (EMPEROR-Preserved trial); Solomon, S. D., et al. (2022). Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine, 387(12), 1089-1098. (DELIVER trial)
  • Vericiguat: Armstrong, P. W., et al. (2020). Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 382(20), 1883-1893. (VICTORIA trial)
  • IV Iron: Ponikowski, P., et al. (2020). Ferric Carboxymaltose for Iron Deficiency at Discharge after Acute Heart Failure: A Multicentre, Double-Blind, Randomised, Controlled Trial. The Lancet, 396(10266), 1895-1905. (AFFIRM-AHF trial)
• Reviews:
  • Braunwald, E. (2017). Heart Failure. Journal of the American College of Cardiology, 70(11), 1334-1342.
  • Jessup, M., & Brozena, S. (2003). Heart Failure. New England Journal of Medicine, 348(22), 2207-2218.